IBEX 35
11.104,60 +120,90 (+1,10%) Euro Stoxx 50
4.972,24 +33,23 (+0,67%) Dólar/Euro
1,0733 0,0000 (-0,00%) Petróleo Brent
89,56 +0,55 (+0,62%) Oro
2.359,30 +16,80 (+0,72%) Bitcoin EUR
59.828,02 +508,56 (+0,86%)
Seres Therapeutics, Inc. (MCRB)
Después del cierre:
Seres Therapeutics, Inc.
101 Cambridgepark Drive
Cambridge, MA 02140
United States
617 945 9626
https://www.serestherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 233
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Eric D. Shaff M.B.A. | President, CEO & Director | 1,02M | N/A | 1976 |
| Dr. Lisa von Moltke M.D. | Executive VP & Chief Medical Officer | 725,15k | N/A | 1959 |
| Dr. Teresa L. Young Ph.D., R.Ph. | Executive VP and Chief Commercial & Strategy Officer | 606,33k | N/A | 1967 |
| Ms. Marella Thorell | Executive VP & CFO | N/A | N/A | 1967 |
| Dr. David S. Ege Ph.D. | Executive VP & Chief Technology Officer | 142,71k | N/A | 1975 |
| Dr. Matthew R. Henn Ph.D. | Executive VP & Chief Scientific Officer | 643,83k | N/A | 1975 |
| Mr. Carlo Tanzi Ph.D. | Investor Relations Officer | N/A | N/A | N/A |
| Mr. Thomas J. DesRosier Esq., J.D. | Chief Legal Officer, Executive VP & Secretary | 719,55k | N/A | 1955 |
| Ms. Caroline Holda | Assistant General Counsel | N/A | N/A | N/A |
Descripción
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Seres Therapeutics, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 2; Tablero: 6; Derechos de los accionistas: 8; Compensación: 9.
